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Abstract
Objective
To determine whether serum magnesium and calcium concentrations are causally associated
with ischemic stroke or any of its subtypes using the mendelian randomization approach.
Methods
Analyses were conducted using summary statistics data for 13 single-nucleotide polymorphisms
robustly associated with serum magnesium (n = 6) or serum calcium (n = 7) concentrations.
The corresponding data for ischemic stroke were obtained from the MEGASTROKE con-
sortium (34,217 cases and 404,630 noncases).
Results
In standard mendelian randomization analysis, the odds ratios for each 0.1 mmol/L (about 1
SD) increase in genetically predicted serum magnesium concentrations were 0.78 (95% con-
fidence interval [CI] 0.69–0.89; p = 1.3 × 10−4) for all ischemic stroke, 0.63 (95%CI 0.50–0.80;
p = 1.6 × 10−4) for cardioembolic stroke, and 0.60 (95% CI 0.44–0.82; p = 0.001) for large
artery stroke; there was no association with small vessel stroke (odds ratio 0.90, 95% CI
0.67–1.20; p = 0.46). Only the association with cardioembolic stroke was robust in sensitivity
analyses. There was no association of genetically predicted serum calcium concentrations with
all ischemic stroke (per 0.5 mg/dL [about 1 SD] increase in serum calcium: odds ratio 1.03,
95% CI 0.88–1.21) or with any subtype.
Conclusions
This study found that genetically higher serum magnesium concentrations are associated with
a reduced risk of cardioembolic stroke but found no significant association of genetically higher
serum calcium concentrations with any ischemic stroke subtype.
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Growing evidence indicates that the essential minerals mag-
nesium and calcium may have a role in cardiovascular disease.
Magnesium, the second most predominant intracellular cat-
ion, can influence the cardiovascular system through vascular
tone, blood pressure, endothelial function, platelet aggrega-
tion and coagulation, cardiac arrhythmias, and glucose and
insulinmetabolism.1–3 Calcium, the most abundantmineral in
the body, has an essential role in the coagulation system,
intracellular signaling, and muscle contraction, but is also
associated with some pathologic processes such as carotid
artery plaques4,5 and calcifications.6
Magnesium and calcium supplementation leads to a rise in
blood concentrations of these minerals.7–9 Therefore, any as-
sociation of circulating magnesium and calcium concentrations
with risk of stroke, an enormous public health problem, can
have important public health and clinical implications. Findings
from observational epidemiologic studies indicate that low
serum magnesium concentrations10–12 and slightly elevated
serum calcium concentrations13,14 are associated with increased
risk of stroke. Limited data from randomized controlled trials
further indicate that calcium supplementation might increase
stroke risk.4 However, given the observational design of the
majority of available studies on magnesium and calcium in
relation to risk of stroke, it is uncertain whether the observed
associations are causal and independent of other risk factors, and
not biased by reverse causation.
Mendelian randomization (MR) is a genetic epidemiologic
method that exploits genetic variants influencing the modifiable
exposure of interest as unbiased proxies for the exposure to infer
causality.5,15 This method has been utilized to demonstrate that
serum magnesium16 and serum calcium17 concentrations are
associated with respectively decreased and increased risk of
coronary artery disease, but has not been used to determine
whether circulating levels of these minerals are associated
with risk of ischemic stroke. We applied a 2-sample MR
approach to investigate whether serum magnesium and
calcium concentrations are causally associated with ische-
mic stroke as a whole or any of its main subtypes.
Methods
Single nucleotide polymorphism selection and
data sources
We selected all single nucleotide polymorphisms (SNPs) as-
sociated with serum magnesium or calcium concentrations at
Glossary
CI = confidence interval; GWAS = genome-wide association study; MR = mendelian randomization; OR = odds ratio;
SIMEX = simulation extrapolation; SNP = single nucleotide polymorphism.
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genome-wide significance (p < 5 × 10−8) in the largest pub-
lished genome-wide association studies (GWAS) on these
minerals.18,19 The GWAS on serum magnesium identified 6
significant and independent (i.e., not in linkage disequilib-
rium) SNPs, explaining 1.6% of the variance in serum mag-
nesium concentrations, in the joint analysis of the discovery
and replication cohorts including 23,829 individuals of Eu-
ropean ancestry.18 The GWAS on serum calcium identified 7
replicated and independent SNPs, explaining 0.9% of the
variance in serum calcium concentrations, in up to 61,079
individuals of European ancestry.19
From theMEGASTROKE consortium,20 we obtained summary
statistics data for stroke for the 13 SNPs. To reduce potential bias
caused by population stratification, we restricted the stroke
dataset to individuals of European ancestry. Thus, our analyses
included data from up to 404,630 noncases and 34,217 ischemic
stroke cases, subtyped into cardioembolic stroke (n = 7,193),
large artery stroke (n = 4,373), and small vessel stroke (n =
5,386). Stroke subtypes were classified according to the Trial of
Org 10172 in Acute Stroke Treatment criteria.21
Standard protocol approvals, registrations,
and patient consents
Each study included in the GWAS used in the present study
was approved by an institutional review board, and all par-
ticipants had provided informed consent.
Statistical analysis
The primary analyses were conducted using the inverse-
variance weighted method (hereafter referred to as stan-
dard MR analysis), which gives accurate estimates if all
SNPs satisfy the instrumental variable assumptions (data
available from Open Science Framework, figure e-1, osf.io/
b57sq/).22 In sensitivity analyses, we used other MR
approaches, including the following: (1) the weighted
median method, which provides consistent estimates if at
least 50% of the weight in the analysis comes from valid
instrumental variables22; (2) the heterogeneity-penalized
model averaging method, which gives consistent estimates
if a plurality of the instrumental variables are valid23; and
(3) the MR-Egger method, which can detect and adjust for
pleiotropy.22,24 The MR-Egger analysis is disposed to re-
gression dilution bias. The degree of dilution bias was assessed
with the I2GX statistic.
25 I2GX values below 0.9 were consid-
ered substantial dilution, and the simulation extrapolation
(SIMEX) method was used to adjust the estimates for di-
lution bias.25 The MR-PRESSO method was used to detect
potential outliers.26 Moreover, we conducted sensitivity
analyses excluding SNPs with pleiotropic associations with
possible confounders or intermediates of the exposure-
stroke relationship.
Odds ratios (ORs) were scaled per 0.1 mmol/L (about 1 SD)
increase in serum magnesium concentrations and 0.5 mg/dL
(about 1 SD) increase in serum calcium concentrations. A
Bonferroni-corrected level of significance of less than 0.006
(correcting for 2 exposures and 4 outcomes) was considered
statistically significant. Associations of the 13 individual
SNPs with the 4 outcomes were considered statistically
significant at p values of less than 9.6 × 10−4. The analyses
were conducted using Stata software (StataCorp, College
Station, TX) and the MendelianRandomization package27
for R. Statistical power was calculated using the method
proposed by Brion et al.28
Data availability
All data generated or analyzed during this study are included
in the main manuscript and its supplementary information
files.
Results
Statistical power
We had 100% power to detect anOR of any ischemic stroke of
0.80 for serum magnesium levels and 1.25 for serum calcium
levels. The statistical power in analyses of ischemic stroke
subtypes is shown in data available from Open Science
Framework (table e-1, osf.io/b57sq/).
Serum magnesium
Of the 6 SNPs associated with serum magnesium concen-
trations, rs7965584 (near ATP2B1) was statistically signifi-
cantly associated with all ischemic stroke, large artery stroke,
and small vessel stroke; rs4072037 (MUC1) was associated
with cardioembolic stroke; and rs448378 (MDS1) was asso-
ciated with large artery stroke (data available from Open
Science Framework, table 2 and figure e-1, osf.io/b57sq/). In
the standard MR analysis, genetically predicted serum mag-
nesium concentrations were associated with all ischemic
stroke, cardioembolic stroke, and large artery stroke, but not
with small vessel stroke (figure 1). The ORs per genetically
predicted 0.1 mmol/L (about 1 SD) increase in serum mag-
nesium concentrations were 0.78 (95% confidence interval
[CI] 0.69–0.89; p = 1.3 × 10−4) for all ischemic stroke, 0.63
(95% CI 0.50–0.80; p = 1.6 × 10−4) for cardioembolic stroke,
0.60 (95%CI 0.44–0.82; p = 0.001) for large artery stroke, and
0.90 (95% CI 0.67–1.20; p = 0.46) for small vessel stroke
(figure 1). Only the association with cardioembolic stroke
remained in sensitivity analyses (figure 1).
The I2GX value from the MR-Egger analysis was 0.87, in-
dicating 13% dilution of the estimates. The MR-Egger anal-
ysis, with adjustment for dilution bias using the SIMEX
method, provided imprecise estimates (data available from
Open Science Framework, table e-3, osf.io/b57sq/). In this
analysis, genetically predicted serum magnesium concen-
trations were associated with cardioembolic stroke but the CI
included the null (OR 0.66, 95% CI 0.21–2.10); there was no
evidence of directional pleiotropy (data available from Open
Science Framework, table e-3). In contrast, directional plei-
otropy was detected in the analysis of large artery stroke, and
this was not explained by any single SNP (data available from
Open Science Framework, table e-3).
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The MR-PRESSO analysis identified potential outlying SNPs
(at p < 0.10), which varied for different subtypes (data
available from Open Science Framework, table e-4, osf.io/
b57sq/). The association of genetically predicted serum
magnesium concentration with cardioembolic stroke per-
sisted after exclusion of the outlier in TRPM6 (OR 0.56, 95%
CI 0.43–0.73). The association also remained after exclusion
of 2 SNPs associated with estimated glomerular filtration rate
and 1 SNP associated with blood pressure and serum urate
levels, but was attenuated after omitting 2 SNPs associated
with atrial fibrillation (OR 0.73, 95% CI 0.52–1.03) (data
available from Open Science Framework, table e-5).
Serum calcium
None of the calcium-associated SNPs was statistically signif-
icantly associated with ischemic stroke as a whole or any
subtype (data available from Open Science Framework, table
e-6 and figure e-2, osf.io/b57sq/). There were no associations
between genetically predicted serum calcium concentrations
and any stroke outcome in the standardMR analysis (figure 2).
The OR of all ischemic stroke per genetically predicted 0.5
mg/dL (about 1 SD) increase in serum calcium concen-
trations was 1.03 (95% CI 0.88–1.21; p = 0.68). The lack of
association remained in sensitivity analyses (figure 2), and
there was no evidence of directional pleiotropy in the MR-
Egger analysis (data available from Open Science Framework,
table e-7, osf.io/b57sq/). The I2GX value was 0.96, indicating
no significant dilution bias in the MR-Egger analysis. No
associations of genetically predicted serum calcium con-
centrations with any stroke outcome were observed after
exclusion of the SNP in GCKR, which has pleiotropic asso-
ciations with potential confounders (e.g., blood lipids and
type 2 diabetes) (data available from Open Science Frame-
work, table e-8).17 No outliers were identified in the MR-
PRESSO analysis.
Discussion
Findings of this MR study showed a consistent association
between genetically higher serum magnesium concentrations
and reduced risk of cardioembolic stroke but not other sub-
types. Genetically predicted serum calcium concentrations
were not associated with any ischemic stroke subtype or with
ischemic stroke overall.
Although several observational prospective studies have
reported that low circulating magnesium concentrations10–12
and lowmagnesium intake29 are associated with increased risk
of stroke, data on ischemic stroke subtypes are scarce.12 In the
Nurses’ Health Study, low plasma magnesium concentrations
(<0.82 mmol/L) were associated with an approximately 70%
Figure 1 Association between genetically predicted serum magnesium concentrations and ischemic stroke and its
subtypes
ORs are per genetically predicted 0.1
mmol/L (about 1 SD) increase in se-
rummagnesium concentrations. CI =
confidence interval; HetPen = het-
erogeneity-penalized model-averag-
ing; IVW = inverse variance weighted
(standard mendelian randomization
method); OR = odds ratio; WM =
weighted median.
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to 80% increased risk of embolic and thrombotic stroke,12
supporting our findings. Previous observational studies were
limited by possible residual confounding because low mag-
nesium concentrations and magnesium intake are correlated
with potential risk factors for stroke.10–12
Magnesium may in part reduce the risk of cardioembolic
stroke through its antiarrhythmic effects1,3 and via atrial fibrilla-
tion. Low serum magnesium concentrations are associated with
increased risk of atrial fibrillation,30,31 which is a strong risk factor
for cardioembolic stroke. Two of the magnesium-associated
SNPs were significantly associated with atrial fibrillation, in-
cluding the SNPs in theMUC1 (p = 0.02) and SHROOM3 (p =
2.4 × 10−4) genes, with the allele associated with higher serum
magnesium concentrations being associated with lower risk of
atrial fibrillation.32 The association between genetically predicted
serum magnesium concentrations and cardioembolic stroke was
attenuated after exclusion of those 2 SNPs, suggesting that the
association may partly be mediated by atrial fibrillation.
Magnesium also has anticoagulant and antiplatelet
properties.1,3 Magnesium is considered to be nature’s calcium
blocker as it suppresses many of the physiologic actions of
calcium.1,3 For example, calcium promotes blood coagulation,
whereas magnesium suppresses blood clotting and thrombus
formation and reduces platelet aggregation, the synthesis of
platelet agonist thromboxane A2, von Willebrand factor
binding to collagen, and thrombin-stimulated calcium
influx.1,3,33–35 Antithrombotic effects may lead to reduction in
risk of both cardioembolic and large artery stroke. A signifi-
cant association between genetically predicted serum mag-
nesium concentrations and large artery stroke was observed in
the standard MR analysis, but this association did not persist
in sensitivity analyses.
Other possible mechanisms whereby high serum magnesium
concentrations may reduce ischemic stroke risk include im-
provement of endothelial function36,37 and reduction in blood
pressure,36,38 atherosclerotic calcification,39 arterial stiff-
ness,40 oxidative stress,41 fasting glucose concentration,38 in-
sulin resistance,42 and risk of type 2 diabetes.43,44 Some of
those beneficial effects may also lead to a reduction in small
vessel stroke, which was not observed in this study.
TheMR design has not been previously used to determine the
association between serum calcium concentration and risk of
ischemic stroke, but a few observational prospective studies
have examined the association between serum calcium con-
centrations and risk of stroke.13,14 In a cohort of about
440,000 Swedish adults, high (≥2.40 mmol/L) vs low (<2.25
mmol/L) serum calcium concentrations were associated with
a 12% increased risk of incident ischemic stroke and with
Figure 2 Association between genetically predicted serum calcium concentrations and ischemic stroke and its subtypes
ORs are per genetically predicted 0.5
mg/dL (about 1 SD) increase in serum
calcium concentrations. CI = confi-
dence interval; HetPen = heteroge-
neity-penalized model-averaging;
IVW = inverse variance weighted
(standard mendelian randomization
method); OR = odds ratio; WM =
weighted median.
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a 40% increased risk of fatal ischemic stroke.14 Another cohort
of 13,288 US adults showed a 16% increase in risk of total
stroke per 1-SD increase in serum calcium concentrations.13
The association of genetically predicted serum calcium con-
centration with cardioembolic stroke in the present study was
of similar magnitude, though nonsignificant, as the association
with stroke in previous observational studies13,14 and with
coronary artery disease in a previousMR study (OR 1.25, 95%
CI 1.08–1.45).17 The estimates for serum calcium and car-
diometabolic stroke are also similar to those for calcium
supplementation and stroke from a meta-analysis of 8 ran-
domized controlled trials (relative risk 1.15, 95% CI
1.00–1.32; p = 0.06).4 It is unclear why genetically predicted
serum calcium concentrations were not associated with large
artery stroke, which like coronary heart disease is related to
atherosclerosis. A possibility is that we may have overlooked
an association because of low power (data available from
Open Science Framework, table e-1, osf.io/b57sq/).
A major strength of this MR study is that biases that can be of
concern in conventional observational studies were avoided.
Other important strengths are the large number of cases of
ischemic stroke and that associations with ischemic stroke
subtypes could be investigated.
A limitation is that statistical power was low in the analyses
of ischemic stroke subtypes. The power was particularly
low in the analyses of calcium because the SNPs only
explained a small proportion of the variance (0.9%) in
serum calcium levels. Hence, we cannot rule out that we
may have overlooked weak associations between geneti-
cally predicted serum calcium concentrations and ischemic
stroke subtypes. Another shortcoming is that the bi-
ological function of several of the genetic loci associated
with serum magnesium and calcium levels are unknown
(data available from Open Science Framework, table e-9,
osf.io/b57sq/).
The reliability of MR results relies on 3 main assumptions
(data available from Open Science Framework, figure e-1, osf.
io/b57sq/), which can be violated by population stratification,
canalization, and pleiotropy. Population stratification was
minimized because we restricted the study populations to
European-descent individuals. We could not directly test
whether canalization may have influenced the results. Cana-
lization refers to compensatory processes during development
that alleviate the genetic effect. Such feedback mechanisms
would bias the results toward the null and cannot explain the
observed association between serum magnesium concentra-
tion and cardioembolic stroke. Pleiotropy occurs when a ge-
netic variant is associated with more than one phenotype. We
conducted several sensitivity analyses to explore and adjust for
pleiotropy. The association of genetically predicted serum
magnesium concentrations with cardioembolic stroke, but
not the other subtypes or overall stroke, was robust in these
sensitivity analyses and the MR-Egger analysis provided no
evidence of directional pleiotropy.
This study found evidence that genetically higher serum
magnesium concentrations may be associated with a reduced
risk of cardioembolic stroke. Genetically higher serum cal-
cium concentrations were not associated with ischemic stroke,
but the existence of an effect of low magnitude cannot be
ruled out.
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